NewsRx

Search our medical news database

Age-Related Macular Degeneration

SBIR grant to fund treatment of ocular neovascularization diseases

Published in Cancer Weekly, July 20th, 2004

Intradigm Corp. announced that it has been awarded a phase I small business innovation research (SBIR) grant by the National Eye Institute to support development of the company's lead antiangiogenesis siRNA therapeutic product.

Dr. Qingquan Tang, group leader of virology at Intradigm, is the principle investigator of this grant titled "Development of RNAi Therapeutics for Eye Neovascularization Diseases."

This lead product has demonstrated strong antiangiogenesis effect through a dual targeting to both neovasculature in eyes and factors in VEGF pathway. VEGF pathway is the validated therapeutic target for treatment of angiogenesis related...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook